Microcarrier culture system for human influenza vaccine

描述（申请人提供）：本文提出的研究目标 是开发一种基于微载体-生物反应器-细胞培养的方案， 使人流感疫苗的生产快速、高效、低成本。 目前，几乎所有的人流感病毒疫苗都是在 带胚蛋联邦政府和世界卫生组织 积极寻求流感疫苗生产的替代细胞培养方法 因为卵源疫苗存在几个问题。细胞 基于培养的方案，具有快速实现大规模的潜力， 在流感大流行的情况下将是非常宝贵的。新型微载体 由SoloHill（在授权CA 74595下）开发的基质（Hillex 以支持多种低粘附细胞在细胞中的附着和生长， 无血清培养基，并显示了这种应用的前景。实现这一 研究目标，将执行以下两个具体目标。 具体目标一。证明培养两种不同细胞类型的可行性 (Vero和MDCK），并鉴定关键细胞培养物 变量，将提供高细胞产量在此基板下无血清 条件 具体目标二。证明在Vero和MDCK上的流感病毒生产 在Hillex微载体上维持的细胞（其他人已经证明， Vero或MDCK细胞可用于繁殖人流感病毒） 在优化的生物反应器型条件下。 拟议商业应用：不可用

DESCRIPTION (Provided by Applicant): The goal of the research herein proposed is to develop a microcarrier - bioreactor - cell culture-based protocol that enables the rapid, efficient, low cost production of human influenza vaccine. Currently, virtually all human influenza virus vaccine is produced in embryonated eggs. The Federal government and the World Health Organization are actively seeking alternative cell culture approaches to flu vaccine production since there are several problems with the egg-derived vaccines. A cell culture-based protocol, with its potential to rapidly achieve large scale, would be invaluable in the case of an influenza pandemic. A new microcarrier substrate (Hillex), developed by SoloHill (under grant CA74595) has been shown to support attachment and growth of a variety of low adhesive cells in sera-free media and shows promise for this application. To achieve this research goal, the following two specific aims will be performed. Specific Aim I. To demonstrate feasibility for growing two different cell types (Vero and MDCK) on Hillex microcarriers and identify critical cell culture variables that will provide high cell yields on this substrate under serum-free conditions. Specific Aim II. To demonstrate influenza virus production on Vero and MDCK cells maintained on Hillex microcarriers (others have demonstrated that either Vero or MDCK cells can feasibly be used to propagate human influenza virus) under optimized bioreactor-type conditions. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE